# 2025年12月22日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 利用 ec3D 重建染色体外 DNA 的三维结构。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422275)
**期刊：** Nature communications
**PMID：** 41422275
**DOI：** 10.1038/s41467-025-67614-7

### 第一部分 原文与翻译

**英文原标题：** Reconstructing the three-dimensional architecture of extrachromosomal DNA with ec3D.

> **英文摘要：**
> Extrachromosomal DNAs (ecDNAs) are circular DNA molecules prevalent in human cancers that drive tumor evolution and drug resistance. Their circular topology, which disrupts topological domains and rewires regulatory circuits, has typically been studied via pairwise interactions. Here we develop ec3D, a computational method for reconstructing three-dimensional ecDNA structures from Hi-C data. Given a candidate ecDNA sequence and whole-genome Hi-C data, ec3D reconstructs spatial structures by maximizing the Poisson likelihood of observed interactions. We validate ec3D using simulated structures, previously characterized cancer cell lines, and microscopy imaging. Our reconstructions reveal that ecDNAs occupy spherical configurations and mediate unique long-range regulatory interactions involved in gene regulation. Through algorithmic innovations, ec3D can resolve complex structures with duplicated segments, identify multi-way interactions, and identify potential intermolecular (trans) interactions. Our findings provide insights into how ecDNA's spatial organization bypasses normal chromosomal constraints and contributes to increased oncogene expression.

> **中文摘要：**
> 染色体外 DNA（ecDNA）是广泛存在于人类癌症中的环状 DNA 分子，能够推动肿瘤进化和耐药性。其环状拓扑结构会破坏拓扑域并重塑调控网络，传统研究通常通过成对相互作用进行探讨。在本研究中，我们开发了 ec3D，这是一种基于 Hi-C 数据重建 ecDNA 三维结构的计算方法。给定候选 ecDNA 序列及全基因组 Hi-C 数据，ec3D 通过最大化观察到的相互作用的泊松似然来重建空间结构。我们利用模拟结构、既往表征的癌细胞系以及显微成像对 ec3D 进行验证。重建结果显示，ecDNA 呈球形构型，并介导在基因调控中起作用的独特长程调控相互作用。通过算法创新，ec3D 能解析含有重复片段的复杂结构，识别多向相互作用及潜在的分子间（反式）相互作用。我们的研究揭示了 ecDNA 的空间组织如何绕过正常染色体限制并促进癌基因表达增加。

### 第二部分 AI 大师评价

该研究旨在通过开发 ec3D 算法，从 Hi-C 数据中精准重建染色体外 DNA 的三维结构。方法上结合统计模型和空间重建策略，系统验证了其在模拟数据、癌细胞系及成像数据中的可靠性。结果表明 ecDNA 呈球形结构，参与独特的长程调控相互作用，为理解其如何促进肿瘤进化提供新视角。研究创新性显著，但后续仍需在原代肿瘤样本中进一步验证其适用性。

---

## 2. 尿路上皮癌中 HER2 靶向抗体药物偶联物敏感性的决定因素

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422272)
**期刊：** Nature communications
**PMID：** 41422272
**DOI：** 10.1038/s41467-025-67643-2

### 第一部分 原文与翻译

**英文原标题：** Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer.

> **英文摘要：**
> HER2, encoded by the ERBB2 gene, is a receptor tyrosine kinase frequently activated in human cancers via gene amplification, mutation, and/or protein overexpression. In an analysis of 42,415 prospectively analyzed solid tumors, we show that 14.5% of urothelial cancers (n = 295/2,035) have oncogenic or likely oncogenic ERBB2 alterations (6.7% ERBB2 mutation, 6.3% amplification of wildtype ERBB2, and 1.5% concurrent mutation and amplification). Discordance of ERBB2 mutational status between primary and metastatic disease sites is common in patients with urothelial cancer as is discordance of ERBB2 mutational status between patient-derived organoid/xenograft models and the tumors from which they were derived. In patient-derived urothelial cancer models, the HER2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan is significantly more effective than the HER kinase inhibitor neratinib. In a real-world cohort of patients with urothelial cancer treated with trastuzumab deruxtecan, co-mutation and amplification of ERBB2 is associated with exceptional clinical response. Our data support expanded clinical trials of HER2-targeted ADCs for urothelial cancers with low HER2 expression, the clinical testing of HER2 ADCs with alternative cytotoxic payloads, and the development of functional precision oncology platforms capable of assessing payload sensitivity pre-treatment as a guide to individualized therapy selection.

> **中文摘要：**
> HER2 由 ERBB2 基因编码，是一种受体酪氨酸激酶，在人类癌症中常因基因扩增、突变和/或蛋白质过度表达而被激活。在对 42,415 例前瞻性分析的实体瘤的研究中，我们发现 14.5% 的尿路上皮癌（n = 295/2,035）具有致癌或可能致癌的 ERBB2 改变（包括 6.7% 的 ERBB2 突变、6.3% 的野生型 ERBB2 扩增，以及 1.5% 的突变与扩增共存）。在尿路上皮癌患者中，原发病灶与转移病灶之间 ERBB2 突变状态的不一致较为常见，同样，患者来源的类器官/异种移植模型与原发肿瘤之间的 ERBB2 突变状态也常存在差异。在患者来源的尿路上皮癌模型中，HER2 靶向抗体药物偶联物（ADC）曲妥珠单抗德鲁替康的疗效显著优于 HER 激酶抑制剂奈拉替尼。在接受曲妥珠单抗德鲁替康治疗的真实世界尿路上皮癌患者队列中，ERBB2 的共突变与扩增与卓越的临床反应显著相关。我们的数据支持在 HER2 低表达的尿路上皮癌中扩大 HER2 靶向 ADC 的临床试验，探索具有替代细胞毒载荷的 HER2 ADC 的临床应用，并推动开发能够在治疗前评估载荷敏感性的功能性精准肿瘤学平台，以指导个体化治疗方案的制定。

### 第二部分 AI 大师评价

该研究旨在解析尿路上皮癌对 HER2 靶向抗体药物偶联物的敏感性机制。研究结合大规模实体瘤基因组分析和患者来源模型，揭示 ERBB2 的突变与扩增在该癌种中的显著比例及异质性。作者发现曲妥珠单抗德鲁替康在模型和临床实践中均优于小分子抑制剂奈拉替尼，且 ERBB2 共突变/扩增与卓越疗效相关。该研究创新性地将基因变异与药物反应关联，为 HER2 靶向治疗的精准应用提供了依据，但仍需通过更大规模临床试验证实其普适性。

---

## 3. 靶向分泌型PLA与EGFR及波形蛋白的相互作用以抑制前列腺肿瘤生长

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422270)
**期刊：** Cell death & disease
**PMID：** 41422270
**DOI：** 10.1038/s41419-025-08280-x

### 第一部分 原文与翻译

**英文原标题：** Targeting secreted PLA interactions with EGFR and vimentin to arrest prostate tumour growth.

> **英文摘要：**
> The secreted phospholipase A human group IIA (hGIIA) is overexpressed in prostate cancer (PCa), where its expression is closely aligned with malignancy. While its enzymatic activity is important in mediating innate immunity, here we highlight that hGIIA contributes to PCa pathology primarily through specific protein-protein interactions. We have developed cyclic peptides cF and c2, derived from the structure of hGIIA, that selectively inhibit these interactions and inhibit PCa growth. hGIIA interacts directly with epidermal growth factor receptor (EGFR), resulting in increased cytosolic PLA-α activation and prostaglandin E production, which is suppressed by c2. Further, vimentin was identified to bind hGIIA in PCa cells, modulating hGIIA intracellular trafficking. c2 binds vimentin, blocking this interaction and initiating vimentin-mediated aggresome formation and apoptosis even in the absence of hGIIA. cF and c2 suppress androgen-sensitive, castrate-resistant and androgen-independent models of tumour growth in vivo at doses as low as 0.1 mg/kg, are non-toxic, orally bioavailable and cell-permeable. Critically, as with hGIIA, EGFR and vimentin are also increasingly expressed as PCa develops, cF and c2 may represent a novel therapeutic option for incurable metastatic castrate resistant PCa. Our findings identify hGIIA as an innate immune effector that regulates both inflammation and PCa progression and describe a novel class of hGIIA protein-protein interaction inhibitor with therapeutic potential in PCa.

> **中文摘要：**
> 分泌型磷脂酶A人IIA组（hGIIA）在前列腺癌（PCa）中过度表达，其表达水平与恶性程度密切相关。尽管其酶活性在介导先天免疫中具有重要作用，但本研究强调，hGIIA主要通过特异性的蛋白–蛋白相互作用促进PCa的病理进展。我们基于hGIIA结构设计并开发了含环肽cF和c2，这些环肽可选择性地抑制这些相互作用并抑制PCa生长。hGIIA可直接与表皮生长因子受体（EGFR）相互作用，导致胞质PLA-α活化增强并促进前列腺素E的生成，而这一作用被c2所抑制。此外，在PCa细胞中发现波形蛋白可结合hGIIA，并调节hGIIA的细胞内转运。c2可与波形蛋白结合，阻断这种相互作用，并在缺乏hGIIA的情况下诱导由波形蛋白介导的聚集体形成及细胞凋亡。cF和c2在体内对雄激素敏感、去势耐受和雄激素非依赖型的肿瘤模型均能有效抑制肿瘤生长，即使在低至0.1 mg/kg的剂量下亦起作用，且具有无毒性、良好的口服生物利用度和细胞通透性。值得注意的是，与hGIIA类似，EGFR和波形蛋白也在PCa进展过程中逐步上调，cF和c2可能成为治疗不可治愈的转移性去势耐药性PCa的新型治疗选项。我们的研究发现hGIIA是一种调控炎症与PCa进展的先天免疫效应分子，并描述了一类具有前列腺癌治疗潜力的新型hGIIA蛋白–蛋白相互作用抑制剂。

### 第二部分 AI 大师评价

该研究旨在阐明分泌型磷脂酶A hGIIA在前列腺癌中的致病机制，并通过靶向其与EGFR及波形蛋白的相互作用来阻断肿瘤生长。作者设计了基于hGIIA结构的环肽cF和c2，证明其可有效抑制蛋白互作并诱导肿瘤细胞凋亡，同时在多种小鼠模型中表现出良好的药代动力学特性。研究创新性地揭示了hGIIA作为免疫效应分子在PCa中的双重作用，并提出了蛋白–蛋白相互作用抑制为新的治疗策略。其局限在于主要依赖动物实验，仍需临床验证其安全性与有效性。

---

## 4. 转硫代谢对于静息内皮细胞抵抗铁死亡至关重要。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422256)
**期刊：** Cell death & disease
**PMID：** 41422256
**DOI：** 10.1038/s41419-025-08333-1

### 第一部分 原文与翻译

**英文原标题：** Transsulfuration metabolism is essential for ferroptosis resistance in quiescent endothelial cells.

> **英文摘要：**
> Angiogenesis, the formation of new blood vessels from pre-existing ones, is a crucial process involved in both physiological and pathological contexts. During angiogenesis, quiescent endothelial cells (QECs) forming the vascular bed begin to proliferate and switch their metabolism to support anabolic and energetic needs in response to growth factors and hypoxic conditions. Recent research has demonstrated that ferroptosis, an iron-dependent form of cell death mediated by lipid peroxidation, can affect angiogenesis. Cysteine, a thiol-containing amino acid, is crucial for the synthesis of sulfur-containing biomolecules that control ferroptosis. Glutathione (GSH), a reducing tripeptide containing a cysteine residue, serves as a cofactor for the enzyme glutathione peroxidase 4 (GPX4) to donate electrons to peroxides of polyunsaturated fatty acyl phospholipids. Cysteine can be acquired from its extracellular oxidized form, cystine, via the glutamate-cystine antiporter (system xCT) or synthesized de novo via the transsulfuration pathway (TSP). However, whether proliferating ECs (PECs) and QECs differentially modulate the cysteine/GSH/GPX4 axis to protect themselves from ferroptosis is still unknown. Our findings revealed that PECs primarily utilize extracellular cystine to synthesize GSH, which is essential for avoiding ferroptosis. In contrast, QECs exhibit a resilient response to cystine starvation by activating the TSP. Interestingly, chronic and severe hypoxia induces ferroptosis resistance in PECs exposed to cystine limitation, mimicking the metabolic profile of QECs. Molecularly, QECs exhibit high NRF2 expression necessary to support TSP under cystine limitation and protect QECs from ferroptosis. In vivo experiments confirm the susceptibility of ECs to cell death by xCT inhibition in a retinal model of sprouting angiogenesis. These findings highlight differential regulation of cysteine metabolism in PECs and QECs and suggest that the cysteine/GSH/GPX4 axis could be a potential therapeutic target for diseases involving angiogenesis.

> **中文摘要：**
> 血管生成，即由已有血管形成新血管的过程，是一个在生理和病理环境中均至关重要的过程。在血管生成过程中，构成血管床的静息内皮细胞（QECs）开始增殖，并在生长因子与缺氧条件的刺激下转变其代谢方式，以支持合成代谢和能量需求。近期研究表明，铁死亡——一种由脂质过氧化介导的、依赖铁的细胞死亡形式——会影响血管生成。半胱氨酸是一种含巯基的氨基酸，对于合成控制铁死亡的含硫生物分子至关重要。谷胱甘肽（GSH）是一种含半胱氨酸残基的还原型三肽，作为谷胱甘肽过氧化物酶4（GPX4）的辅因子，为多不饱和脂酰磷脂的过氧化物提供电子。半胱氨酸可通过谷氨酸-胱氨酸抗转运蛋白系统（xCT）从胞外氧化形式——胱氨酸——摄取，或通过转硫途径（TSP）在细胞内新生合成。然而，增殖内皮细胞（PECs）与静息内皮细胞（QECs）是否以不同方式调控半胱氨酸/GSH/GPX4轴以防御铁死亡，尚不清楚。我们的研究结果显示，PECs 主要利用胞外胱氨酸合成 GSH，这对于避免铁死亡至关重要。相反，QECs 通过激活 TSP 对胱氨酸缺乏表现出强大的适应性反应。有趣的是，长期且严重的缺氧能够诱导在胱氨酸受限条件下的 PECs 产生抗铁死亡能力，其代谢特征与 QECs 相似。从分子层面看，QECs 表现出较高水平的 NRF2 表达，这对于在胱氨酸缺乏情况下维持 TSP 活性并保护 QECs 免受铁死亡至关重要。体内实验在视网膜新生血管模型中证实，抑制 xCT 会导致内皮细胞对细胞死亡的易感性增加。这些发现突出了 PECs 与 QECs 在半胱氨酸代谢调控上的差异，并提示半胱氨酸/GSH/GPX4 轴可能成为涉及血管生成疾病的潜在治疗靶点。

### 第二部分 AI 大师评价

该研究聚焦于不同状态下内皮细胞的铁死亡防御机制，揭示了静息内皮细胞依赖转硫代谢以维持抗铁死亡能力的分子基础。作者通过比较 PECs 与 QECs 的代谢偏好，发现 QECs 在胱氨酸受限及缺氧条件下仍能激活转硫途径，以维持 GSH 合成并抵御铁死亡。研究确认 NRF2 在维持这一代谢适应中的关键作用，并通过体内视网膜血管模型验证了相关机制的生物学意义。该发现为理解血管生成过程中的代谢重编程及铁死亡调控提供了新视角，也为血管相关疾病的潜在治疗靶点开发奠定基础。

---

## 5. 结肠靶向黄芪多糖纳米颗粒通过微生物群重塑和 NF-κB 抑制防止 NAFLD 驱动的肝癌发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422246)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41422246
**DOI：** 10.1186/s13046-025-03608-z

### 第一部分 原文与翻译

**英文原标题：** Colon-Targeted astragalus polysaccharide nanoparticles prevent NAFLD-Driven hepatocarcinogenesis via microbiota remodeling and NF-κB Inhibition.

> **英文摘要：**
> Hepatocellular carcinoma (HCC), often arising from liver fibrosis in nonalcoholic fatty liver disease (NAFLD), remains a leading cause of cancer-related death. Targeting the gut-liver axis offers new therapeutic opportunities to prevent this progression. In this study, colon-targeted chitosan/pectin-based nanoparticles loaded with Astragalus polysaccharide (APs-CS/PT-NPs) were developed to modulate gut microbiota and inhibit liver tumorigenesis. The nanoparticles exhibited robust physicochemical stability and pH-responsive release. In vivo, oral administration of APs-CS/PT-NPs attenuated hepatic steatosis, reduced inflammatory cytokines, and suppressed NAFLD-induced HCC development. 16 S rRNA sequencing revealed restoration of microbial diversity and enhanced production of short-chain fatty acids, especially acetate. Mechanistically, transcriptomic profiling and functional analysis identified acetate as a key mediator, acting via G-protein-coupled receptor 43 (GPR43) to inhibit the NF-κB pathway. These results highlight the therapeutic potential of APs-CS/PT-NPs in modulating the gut-liver axis, rebalancing intestinal microbiota, and suppressing pro-inflammatory signaling. This nanoparticle-based strategy offers a promising food-derived preventive intervention for liver fibrosis-HCC transition.

> **中文摘要：**
> 肝细胞癌（HCC）通常源自非酒精性脂肪性肝病（NAFLD）中的肝纤维化，仍然是导致癌症相关死亡的主要原因之一。靶向肠-肝轴为阻止这一进程提供了新的治疗机会。在本研究中，研究人员开发了负载黄芪多糖的结肠靶向壳聚糖/果胶基纳米颗粒（APs-CS/PT-NPs），以调节肠道微生物群并抑制肝脏肿瘤发生。该纳米颗粒表现出优异的理化稳定性和 pH 响应性释放特性。在体内实验中，口服给药的 APs-CS/PT-NPs 可减轻肝脂肪变性，降低炎性细胞因子水平，并抑制 NAFLD 诱导的 HCC 发展。16S rRNA 测序显示，APs-CS/PT-NPs 可恢复微生物多样性并增强短链脂肪酸（尤其是乙酸盐）的产生。在机制上，转录组分析和功能研究表明乙酸盐是关键介质，可通过激活 G 蛋白偶联受体 43（GPR43）抑制 NF-κB 通路。这些结果强调了 APs-CS/PT-NPs 在调节肠-肝轴、重塑肠道微生物群及抑制促炎信号方面的治疗潜力。这种基于纳米颗粒的策略为预防肝纤维化向肝癌转化提供了一种有前景的食源性干预途径。

### 第二部分 AI 大师评价

该研究旨在通过开发结肠靶向黄芪多糖纳米颗粒，干预 NAFLD 向肝癌的进展。研究采用壳聚糖/果胶材料构建稳定且 pH 响应性的载药系统，并通过动物实验验证了其改善肝脂肪变性、抑制炎症及防止肿瘤形成的效果。16S rRNA 和转录组分析揭示乙酸与 GPR43 介导的 NF-κB 通路抑制为关键机制。该研究创新性地连接了肠道微生态重塑与肝癌预防，为食源性纳米药物在代谢性肝病防控中的应用提供了新思路，但仍需进一步验证其长期安全性与人体转化潜力。

---

## 6. 利用多价性与FcγRIIB相互作用增强抗CD27免疫治疗效力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422231)
**期刊：** Nature communications
**PMID：** 41422231
**DOI：** 10.1038/s41467-025-67882-3

### 第一部分 原文与翻译

**英文原标题：** Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapy.

> **英文摘要：**
> Despite significant clinical progress, checkpoint blockade remains limited by variable response rates, resistance, and toxicity. Activating costimulatory receptors offers a promising alternative to enhance anti-tumor immunity. However, there is insufficient understanding of how to mimic physiological membrane-anchored costimulatory ligands. Here, we describe a strategy for developing effective agonists of the costimulatory receptor CD27 by increasing both antibody valency and FcγRIIB engagement. Engineered anti-CD27 antibodies capable of tetravalent binding to CD27 and selective FcγRIIB association exhibit potent T cell stimulatory activity and anti-tumor efficacy in pre-clinical models, compared to bivalent counterparts. The anti-tumor effects of the tetravalent antibody are mediated through CD8⁺ T cell activation without evidence of regulatory T cell depletion. Mechanistically, whereas the increase in avidity drives more efficient CD27 clustering, FcγRIIB engagement triggers polarization of receptor clusters to the cell-cell interface and reduces receptor internalization. This work provides a framework for developing more effective agonist-based T cell stimulatory therapies.

> **中文摘要：**
> 尽管临床上取得了显著进展，免疫检查点阻断疗法仍受到反应率差异、耐药性及毒性的限制。激活共刺激受体被认为是一种有前景的替代策略，可增强抗肿瘤免疫。然而，如何有效模拟生理性膜锚定的共刺激配体仍缺乏充分理解。在此，我们提出了一种通过同时增加抗体价数和FcγRIIB结合来开发共刺激受体CD27有效激动剂的策略。经工程改造的抗CD27抗体，具备与CD27四价结合及选择性结合FcγRIIB的能力，与双价抗体相比，在临床前模型中显示出强大的T细胞刺激活性及显著的抗肿瘤效应。该四价抗体的抗肿瘤效应通过激活CD8⁺ T细胞实现，且未见调节性T细胞耗竭的证据。从机制上看，亲和力的增强促进了更高效的CD27聚集，而FcγRIIB的结合则诱导受体簇极化至细胞间接触界面并降低受体内化速率。本研究为开发更高效的基于激动剂的T细胞共刺激治疗提供了新的理论框架。

### 第二部分 AI 大师评价

该研究旨在通过优化抗体结构特性来提升抗CD27免疫治疗的效能。作者利用工程化手段，增强抗体的多价性并结合FcγRIIB，实现对CD27更高效的聚集与信号传导，促进CD8⁺ T细胞活化，从而提升抗肿瘤反应。研究机制阐述清晰，揭示了FcγRIIB参与受体空间重构和内化调控的新作用。其创新之处在于将抗体工程与免疫受体生物物理调控相结合，为激动型免疫疗法设计提供了可复制的策略，但仍需临床验证其安全性与有效性。

---

## 7. 抑制 OTUD7A/KDM5B/GABPA 轴通过诱导铁死亡增强 KRAS 突变型肺腺癌对顺铂的敏感性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422226)
**期刊：** Cell death & disease
**PMID：** 41422226
**DOI：** 10.1038/s41419-025-08337-x

### 第一部分 原文与翻译

**英文原标题：** Suppressing the OTUD7A/KDM5B/GABPA axis enhances the sensitivity of cisplatin through inducing ferroptosis in KRAS-mutant LUAD.

> **英文摘要：**
> KRAS-mutant lung adenocarcinoma (LUAD), due to its evolution of more complex antioxidant metabolic mechanisms, exhibits poorer sensitivity to conventional platinum-based drugs compared to other types of LUAD. Ferroptosis, as a means of inducing cell death in cancer therapy, shows unique features and potential therapeutic effects compared to the conventional form of apoptosis, which is frequently obstructed by drug resistance. In human KRAS-mutant LUAD cell lines and mouse models, we found that the deubiquitinase OTU deubiquitinase 7A (OTUD7A) precisely regulates the lysine demethylase 5B (KDM5B). Inhibition of KDM5B expression increases the H4K20me3 level, which in turn downregulates the expression of transcription factor GABPA associated with mitochondrial function, ultimately promoting the production of more Reactive Oxygen Species (ROS) by mitochondria and inducing ferroptosis. Additionally, in in vivo organoid models, cisplatin (CDDP) induced ferroptosis combined with GABPA inhibition demonstrated superior anticancer effects compared to conventional platinum-based drugs. This research identifies new targets and regulatory networks that hold promise for developing ferroptosis-based therapies for KRAS-mutant LUAD.

> **中文摘要：**
> KRAS 突变型肺腺癌（LUAD）由于其演化出更为复杂的抗氧化代谢机制，相较于其他类型的 LUAD，对传统铂类药物表现出较差的敏感性。铁死亡作为癌症治疗中一种诱导细胞死亡的方式，与常规的凋亡相比，具有独特特征及潜在治疗效果，而凋亡常因药物耐受而受阻。在人类 KRAS 突变型 LUAD 细胞系及小鼠模型中，我们发现去泛素化酶 OTU 去泛素化酶 7A（OTUD7A）可精确调控赖氨酸去甲基化酶 5B（KDM5B）。抑制 KDM5B 的表达会提高 H4K20me3 水平，进而下调与线粒体功能相关的转录因子 GABPA 的表达，最终促进线粒体产生活性氧（ROS）并诱导铁死亡。此外，在体内类器官模型中，顺铂（CDDP）诱导的铁死亡结合 GABPA 抑制相比传统铂类药物显示出更优的抗癌效果。本研究揭示了新的靶点与调控网络，对发展基于铁死亡的 KRAS 突变型 LUAD 治疗策略具有潜在价值。

### 第二部分 AI 大师评价

该研究聚焦于 KRAS 突变型肺腺癌的化疗耐药机制，揭示了 OTUD7A/KDM5B/GABPA 轴在顺铂敏感性及铁死亡调控中的关键作用。研究通过细胞与动物模型实验证实抑制该分子通路可显著增强顺铂诱导的铁死亡。机制层面创新性在于连接了表观遗传调控、线粒体功能及氧化应激的交互网络。结果为开发针对 KRAS 突变型 LUAD 的铁死亡靶向治疗提供了新的潜在方向，但仍需进一步临床验证其安全性与转化可行性。

---

## 8. LAMP1通过增强DNA-PKcs介导的AKT磷酸化及VEGFC分泌促进食管鳞状细胞癌的淋巴结转移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422118)
**期刊：** Oncogene
**PMID：** 41422118
**DOI：** 10.1038/s41388-025-03664-x

### 第一部分 原文与翻译

**英文原标题：** LAMP1 enhances DNA-PKcs-mediated AKT phosphorylation and VEGFC secretion to promote lymph node metastasis in esophageal squamous cell carcinoma.

> **英文摘要：**
> Lymph node metastasis (LNM) is a major determinant of poor prognosis in esophageal squamous cell carcinoma (ESCC), with patients remaining at high risk of postoperative recurrence in the absence of reliable predictors or effective interventions. To address this unmet clinical need, we perform proteomic and bioinformatic analyses and identify lysosome-associated membrane protein 1 (LAMP1) as a critical driver of LNM in ESCC. LAMP1 is markedly overexpressed in primary tumors that with LNM and correlates with worse survival outcomes across independent cohorts. Gain- and loss-of-function experiments demonstrate that LAMP1 promotes lymphangiogenesis and lymphatic metastasis both in vitro and in vivo. Mechanistically, LAMP1 interacts with DNA-PKcs, mediates AKT activation, leading to VEGFC upregulation and secretion, thereby driving lymphangiogenesis and metastasis. Importantly, treatment with the LAMP1 inhibitor Parishin C significantly suppresses LNM in preclinical ESCC models. These findings uncover a previously unrecognized LAMP1/DNA-PKcs/AKT/VEGFC signaling axis that promotes ESCC progression and highlight LAMP1 as a promising biomarker and therapeutic target for preventing LNM and improving patient outcomes.

> **中文摘要：**
> 淋巴结转移（LNM）是食管鳞状细胞癌（ESCC）预后不良的主要决定因素，在缺乏可靠预测指标或有效干预措施的情况下，患者术后仍面临较高复发风险。为解决这一未被满足的临床需求，我们进行了蛋白质组学和生物信息学分析，并鉴定出溶酶体相关膜蛋白1（LAMP1）是ESCC中LNM发生的关键驱动因子。发现LAMP1在伴有LNM的原发肿瘤中明显高表达，并且在多个独立队列中与较差的生存结局相关。功能获得与缺失实验表明，LAMP1在体内外均能促进淋巴管生成和淋巴转移。在机制上，LAMP1与DNA-PKcs相互作用，介导AKT活化，从而诱导VEGFC上调与分泌，进而驱动淋巴管生成和转移。重要的是，使用LAMP1抑制剂Parishin C的治疗在ESCC的临床前模型中显著抑制了LNM的发生。这些发现揭示了先前未被认识的LAMP1/DNA-PKcs/AKT/VEGFC信号轴在促进ESCC进展中的作用，并强调了LAMP1作为预防LNM及改善患者预后的潜在生物标志物和治疗靶点的价值。

### 第二部分 AI 大师评价

本研究通过多组学方法系统揭示了LAMP1在食管鳞状细胞癌淋巴结转移中的关键作用。作者发现LAMP1通过与DNA-PKcs相互作用激活AKT信号通路，促进VEGFC的表达与分泌，从而增强肿瘤的淋巴管生成与扩散。抑制剂Parishin C在动物模型中有效阻断此过程，展示了潜在的治疗前景。研究创新地定义了LAMP1/DNA-PKcs/AKT/VEGFC信号轴，为ESCC淋巴转移的诊疗提供了新方向，但仍需在临床验证其药物可行性与安全性。

---

## 9. 染色体着丝粒拷贝数扩增与 HER2 阳性转移性乳腺癌患者的卓越应答相关。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422117)
**期刊：** Oncogene
**PMID：** 41422117
**DOI：** 10.1038/s41388-025-03667-8

### 第一部分 原文与翻译

**英文原标题：** Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patients.

> **英文摘要：**
> Metastatic breast cancer (MBC) is generally an incurable neoplasm. A small cohort of patients with HER2-positive MBC, however, achieve such prolonged remission without relapse following anti-HER2 therapy and chemotherapy, that it is speculated they might be cured. The genomes of these patients might provide insights into the underlying mechanisms for their successful treatment. Here, a total of 243 HER2-positive patients diagnosed with MBC between 2000 and 2015 were studied. Of these, 29 patients were identified as exceptional responders (ExR) with an overall survival (OS) > 60 months and no evidence of relapse, 54 patients with an OS > 60 months but who relapsed or developed progressive disease were defined as exceptional survivors (ExS), and 160 patients with an OS < 60 months were identified as short-term responders (STR). Whole-Genome Sequencing and centromere copy number (CCN) analysis was performed on 27 patients (12 ExR; 4 ExS; 11 STR). A significant amplification was observed in the centromeric regions of ExR, exhibiting higher CCN compared to the ExS and STR. Digital PCR validation of chromosome 4 centromere region D4Z1 copy number was not associated with ExR OS. Our results suggest that the amplification of centromere regions are associated with very prolonged remission and survival in patients with HER2-positive MBC.

> **中文摘要：**
> 转移性乳腺癌（MBC）通常是一种不可治愈的肿瘤。然而，一小部分 HER2 阳性 MBC 患者在接受抗 HER2 治疗和化疗后，可获得异常持久且无复发的缓解，因此推测他们可能已被治愈。这些患者的基因组可能为其成功治疗的潜在机制提供洞见。本研究纳入了 2000 年至 2015 年间被诊断为 HER2 阳性 MBC 的 243 名患者。其中，29 例被确定为卓越应答者（ExR），其总生存期（OS）超过 60 个月且无复发证据；54 例总生存期超过 60 个月但出现复发或疾病进展的患者被定义为卓越生存者（ExS）；160 例总生存期少于 60 个月的患者被定义为短期应答者（STR）。研究对 27 名患者（12 ExR；4 ExS；11 STR）进行了全基因组测序及着丝粒拷贝数（CCN）分析。结果显示，ExR 的着丝粒区域存在显著扩增，其 CCN 明显高于 ExS 和 STR。染色体 4 着丝粒区域 D4Z1 拷贝数的数字 PCR 验证结果与 ExR 的总生存期无关。本研究结果提示，着丝粒区域的扩增与 HER2 阳性 MBC 患者的超长期缓解和生存相关。

### 第二部分 AI 大师评价

本研究旨在探讨 HER2 阳性转移性乳腺癌患者中，染色体着丝粒拷贝数扩增与异常疗效的关联。研究通过比较不同生存期群体（ExR、ExS、STR）的全基因组测序数据，发现卓越应答者的着丝粒区存在显著拷贝数扩增。该发现提示基因组层面的染色体稳定性或扩增模式可能与极佳的治疗反应相关。研究的创新性在于首次将着丝粒拷贝数放入 HER2 阳性 MBC 的疗效预后研究框架中，但样本量较小且机制尚需进一步验证。

---

## 10. 人工智能在非洲健康领域中通过移动技术与社交媒体的范围性综述

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422110)
**期刊：** Nature communications
**PMID：** 41422110
**DOI：** 10.1038/s41467-025-64766-4

### 第一部分 原文与翻译

**英文原标题：** Scoping review of artificial intelligence via mobile technology and social media for health in Africa.

> **英文摘要：**
> The combination of mobile technologies and social media with Artificial Intelligence (AI) opens new opportunities for multi-modal data generation, analysis, and inference for various health applications. To investigate how these tools are being used for health applications in Africa, we conduct a scoping review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) approach. We screen 469 articles and synthesize 116. We include 29 studies documenting the use of a broad range of advanced and straightforward machine-learning techniques to study infectious and chronic diseases such as COVID-19 (4 studies, 13.8%), malaria (5, 17.2%), and cervical cancer (2, 6.9%). Countries with high internet and mobile phone penetration have higher representation. Based on identified gaps, we make research and policy recommendations to enhance the contribution of these tools in advancing health in Africa. These include investing in studies on chronic diseases and implementing frameworks to address geographic inequity.

> **中文摘要：**
> 将移动技术和社交媒体与人工智能（AI）相结合，为多模态数据的生成、分析和推理在多种健康应用中开辟了新的机遇。为了调查这些工具在非洲健康应用中的使用情况，我们按照系统综述与Meta分析首选报告项目（PRISMA）方法进行了一项范围性综述。我们筛选了469篇文献并综合分析了116篇研究。在其中，我们纳入了29项研究，记录了从高级到基础的多种机器学习技术被用于研究传染性疾病和慢性疾病，如COVID-19（4项研究，占13.8%）、疟疾（5项，占17.2%）和宫颈癌（2项，占6.9%）。在互联网和移动电话普及率较高的国家，研究代表性也更强。基于所识别的研究空白，我们提出了促进这些工具在推动非洲健康发展中的研究与政策建议，包括加大对慢性病研究的投入以及建立应对地理不均衡的实施框架。

### 第二部分 AI 大师评价

该研究系统性地评估了人工智能结合移动技术与社交媒体在非洲健康领域的应用现状。研究采用PRISMA方法，筛选大量文献并总结29项具体实践，彰显了跨媒介、跨疾病的AI应用多样性。结果揭示了非洲地区在网络基础设施、疾病类型与研究分布方面的差异，同时提出加强慢性病研究与减少地理不平等的政策建议。其创新性在于整合多领域技术洞见，但数据覆盖与地区代表性仍有限。

---

## 11. 一种可重新编程碱基编辑器编辑模式的插入式系统

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422102)
**期刊：** Nature communications
**PMID：** 41422102
**DOI：** 10.1038/s41467-025-67632-5

### 第一部分 原文与翻译

**英文原标题：** A Plug-in system for reprogramming the editing patterns of base editors.

> **英文摘要：**
> DNA base editors are transformative genome editing tools that enable nucleotide conversions without inducing double-stranded DNA breaks, making them promising for correcting genetic mutations. Current base editors, however, are limited by fixed editing windows and constrained location of deaminases. To address these constraints, we develop a modular system termed Plug-in Base Editor (Plug-in BE), which dynamically programs deaminase positioning via integrating various epitopes and antibody-fused deaminases. This system expands the editing capabilities of base editors by optimizing deaminase's spatial interaction with DNA, leading to improvements in efficiencies, window restrictions, and safety profiles. We validate Plug-in BE's versatility and high fidelity in cancer gene therapy and zebrafish embryo editing, demonstrating its potential as a powerful and adaptable tool for basic research and therapeutic applications. This innovation can generate a series of base editors without extensive protein evolution, positioning Plug-in BE as a significant advancement in the field of genome editing.

> **中文摘要：**
> DNA碱基编辑器是一类具有变革性的基因组编辑工具，能够在不引发DNA双链断裂的情况下实现核苷酸转换，因此在纠正遗传突变方面具有应用前景。然而，现有的碱基编辑器受到固定编辑窗口及脱氨酶定位受限的限制。为解决这些约束，我们开发了一种模块化系统，称为插入式碱基编辑器（Plug-in BE），该系统通过整合多种表位及抗体-脱氨酶融合蛋白，实现脱氨酶定位的动态编程。该系统通过优化脱氨酶与DNA的空间相互作用，拓展了碱基编辑器的编辑能力，从而在编辑效率、窗口限制及安全性方面得到改进。我们在癌症基因治疗及斑马鱼胚胎编辑中验证了Plug-in BE的通用性和高保真性，展示了其作为基础研究及治疗应用强大而灵活工具的潜力。这一创新能够在无需大量蛋白质进化的情况下生成一系列碱基编辑器，标志着Plug-in BE在基因组编辑领域的重要进步。

### 第二部分 AI 大师评价

本研究旨在突破传统碱基编辑器受限的编辑窗口与固定脱氨酶定位问题，通过构建模块化的插入式编辑系统实现编辑模式的动态重编程。作者设计的Plug-in BE系统利用表位与抗体融合技术，灵活调控脱氨酶的空间位置，从而提升编辑效率与特异性。实验在细胞与模式生物中验证了其性能与广泛适用性，突显出其在基因治疗及基础研究中的潜力。该方法的创新性在于摆脱了蛋白进化依赖，为未来精准可控的基因编辑提供了新方向。

---

## 12. MRPL17是线粒体功能的关键调控因子及非小细胞肺癌的新型治疗靶点

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422086)
**期刊：** Cell death & disease
**PMID：** 41422086
**DOI：** 10.1038/s41419-025-08343-z

### 第一部分 原文与翻译

**英文原标题：** MRPL17 is a critical regulator of mitochondrial function and a novel therapeutic target in non-small cell lung cancer.

> **英文摘要：**
> This study investigated the role of the mitochondrial protein MRPL17 (mitochondrial ribosomal protein L17) in non-small cell lung cancer (NSCLC), exploring its expression profile, clinical significance, and therapeutic potential. Transcriptomic analyses of TCGA and single-cell RNA sequencing data revealed significant upregulation of MRPL17 in LUAD (lung adenocarcinoma) and LUSC (lung squamous cell carcinoma) tumor tissues, particularly within malignant epithelial and proliferating cancer cells. Elevated MRPL17 expression correlated with advanced stages, positive lymph node metastasis, and poorer overall survival. In vitro investigations demonstrated that silencing or knockout of MRPL17 attenuated cell viability, proliferation, migration, and invasion in NSCLC cells, while promoting apoptosis. Mechanistically, MRPL17 silencing impaired mitochondrial respiratory function, causing reduced oxygen consumption, diminished Complex I activity, and decreased ATP. These impairments were partially reversible by antioxidant treatment or glucose supplementation. Conversely, MRPL17 overexpression enhanced aggressive cellular phenotypes and mitochondrial energetic output. Bioinformatic analysis and subsequent experiments confirmed COX8A as a direct downstream target of MRPL17, mediating its pro-cancerous effects. In vivo, MRPL17 silencing suppressed NSCLC xenograft growth in nude mice, a phenomenon associated with reduced COX8A levels, mitochondrial dysfunction, heightened oxidative stress, and increased apoptosis. Thus, MRPL17 is an important pro-cancerous target in NSCLC, driving malignant progression through the regulation of mitochondrial function and cellular redox balance, with COX8A identified as a key mediator.

> **中文摘要：**
> 本研究探讨了线粒体蛋白MRPL17（线粒体核糖体蛋白L17）在非小细胞肺癌（NSCLC）中的作用，包括其表达特征、临床意义及治疗潜能。TCGA和单细胞RNA测序数据的转录组学分析显示，MRPL17在肺腺癌（LUAD）和肺鳞状细胞癌（LUSC）肿瘤组织中显著上调，尤其在恶性上皮细胞及增殖中的癌细胞中。MRPL17的高表达与晚期分期、阳性淋巴结转移及较差的总体生存显著相关。体外研究显示，沉默或敲除MRPL17可削弱NSCLC细胞的活性、增殖、迁移和侵袭能力，同时促进细胞凋亡。从机制上，MRPL17沉默损害了线粒体呼吸功能，导致氧耗减少、复合物I活性下降及ATP生成减少。这些损伤可通过抗氧化剂治疗或葡萄糖补充部分逆转。相反，过表达MRPL17可增强细胞攻击性表型及线粒体能量输出。生物信息学分析及后续实验确认COX8A是MRPL17的直接下游靶点，并介导其促癌作用。在体内实验中，MRPL17沉默可抑制裸鼠NSCLC移植瘤生长，此现象与COX8A水平下降、线粒体功能障碍、氧化应激增强及凋亡增加相关。因此，MRPL17是NSCLC中一个重要的促癌靶点，通过调节线粒体功能及细胞氧化还原平衡推动恶性进展，其中COX8A为关键介导分子。

### 第二部分 AI 大师评价

该研究系统揭示了线粒体蛋白MRPL17在非小细胞肺癌发生与进展中的功能及机制，通过多组学分析、体内外实验相结合验证其促癌作用及下游靶点COX8A。结果明确指出MRPL17上调与疾病进展及不良预后密切相关，并通过调控线粒体能量代谢和氧化应激促进肿瘤恶化。该工作为线粒体靶向治疗提供了新思路，具有显著创新性，但后续仍需临床验证其作为治疗靶点的安全性与有效性。

---

## 13. 抗PD-L1/TGF-βRII融合蛋白SHR-1701联合白蛋白结合型紫杉醇和吉西他滨用于晚期胰腺导管腺癌一线治疗的Ib/II期研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422078)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41422078
**DOI：** 10.1038/s41392-025-02530-2

### 第一部分 原文与翻译

**英文原标题：** A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma.

> **英文摘要：**
> Nab-paclitaxel plus gemcitabine (AG) is the standard first-line chemotherapy for advanced or metastatic pancreatic ductal adenocarcinoma and has limited efficacy. This phase 1b/2 study aimed to evaluate SHR-1701 (an anti-PD-L1/TGF-βRII fusion protein) plus AG in this population (NCT04624217). In phase 1b part, the recommended dose of SHR-1701 was identified as 30 mg/kg every 3 weeks, when combined with AG. In phase 2 part, the primary endpoint was objective response rate (ORR). As of Mar 31, 2023, 56 patients were enrolled. Median follow-up was 10.3 months (range, 0.2-24.7). ORR was 32.1% (95% CI, 20.3-46.0). Median progressive-free survival (PFS) was 5.6 months (95% CI, 4.3-6.6), and median overall survival (OS) was 10.3 months (95% CI, 8.8-12.3). Treatment-related adverse events of grade ≥3 were reported in 27 (48.2%) patients, with the most common being decreased neutrophil count. Patients with PD-L1 TPS ≥ 1% showed a higher ORR (66.7% vs. 25.0%), as well as extended median PFS (6.3 vs. 5.3 months) and median OS (18.8 vs. 9.9 months). Additionally, reduction of CA19-9 by at least 80% during treatment and pSMAD2/3 staining intensity of 1+ at baseline were potential monitoring tools and predictive biomarkers for better clinical outcomes, respectively. Tumor-specific T-cell infiltration and pancreatic cancer tumor subtypes were associated with anti-tumor response. The interactions within tumor microenvironment were involved disease progression. Overall, first-line SHR-1701 plus AG showed promising anti-tumor activity and controllable safety in advanced or metastatic pancreatic ductal adenocarcinoma, and features of patients more likely to benefit from the combination were drawn.

> **中文摘要：**
> 白蛋白结合型紫杉醇联合吉西他滨（AG）是晚期或转移性胰腺导管腺癌的标准一线化疗方案，但疗效有限。本Ib/II期研究旨在评估抗PD-L1/TGF-βRII融合蛋白SHR-1701联合AG治疗该类人群的效果（NCT04624217）。在Ib期部分，确立了SHR-1701的推荐剂量为30 mg/kg，每3周给药一次，与AG联合使用。在II期部分，主要终点为客观缓解率（ORR）。截至2023年3月31日，共入组56例患者，中位随访时间为10.3个月（范围：0.2–24.7）。ORR为32.1%（95% CI，20.3–46.0）。中位无进展生存期（PFS）为5.6个月（95% CI，4.3–6.6），中位总生存期（OS）为10.3个月（95% CI，8.8–12.3）。共有27例（48.2%）患者报告了3级及以上与治疗相关的不良事件，其中最常见的是中性粒细胞减少。PD-L1 TPS≥1%的患者显示出更高的ORR（66.7% vs 25.0%）、更长的中位PFS（6.3 vs 5.3个月）及OS（18.8 vs 9.9个月）。此外，治疗期间CA19-9下降≥80%和基线时pSMAD2/3染色强度为1+分别作为潜在的疗效监测和预测性生物标志物。肿瘤特异性T细胞浸润及胰腺癌分子亚型与抗肿瘤反应相关。肿瘤微环境内的相互作用与疾病进展有关。总体而言，一线SHR-1701联合AG在晚期或转移性胰腺导管腺癌中显示出有希望的抗肿瘤活性及可控的安全性，并初步描绘出可能从联合治疗中获益的患者特征。

### 第二部分 AI 大师评价

该研究在标准化疗基础上引入免疫融合蛋白SHR-1701，探索其在晚期胰腺导管腺癌中的一线应用，为免疫治疗拓展至难治性实体瘤提供了重要临床证据。结果显示该组合疗法具有较高的客观缓解率及可控的安全性，尤其在PD-L1阳性亚组中疗效突出。研究还识别出CA19-9下降和pSMAD2/3染色强度等潜在生物标志物，具有一定转化价值。局限性在于样本量有限和无对照设计，仍需进一步随机对照试验验证。

---

## 14. 霍奇金淋巴瘤微环境的基因组尺度空间图谱揭示肿瘤细胞生存因子

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422061)
**期刊：** Nature communications
**PMID：** 41422061
**DOI：** 10.1038/s41467-025-67539-1

### 第一部分 原文与翻译

**英文原标题：** Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors.

> **英文摘要：**
> A central challenge in cancer research is to identify the secreted factors that sustain tumor cell survival. This is best exemplified in Hodgkin lymphoma, where malignant cells constitute a minor fraction of the tumor and rely on signals from the microenvironment for survival. Using genome-wide transcriptional profiling with spatial and single-cell resolution, we show that the neighborhood around malignant cells forms a distinct niche of 31 non-malignant cell types, enriched in helper T cells and myeloid cells, but depleted of plasma cells. Moreover, our spatial analysis nominates IL13 as a candidate survival factor. Recombinant IL13 augments malignant cell growth in vitro, and genome-wide loss-of-function screens across >1000 human cancer cell lines identify IL4R and IL13RA1, heterodimeric components of the IL13 receptor, as uniquely essential in Hodgkin lymphoma. Importantly, blocking antibodies phenocopy genetic inactivation. Our findings provide a biological rationale for testing IL13-directed therapies, which are already FDA-approved, in Hodgkin lymphoma.

> **中文摘要：**
> 癌症研究中的核心挑战之一是识别支持肿瘤细胞生存的分泌因子。霍奇金淋巴瘤是该问题的典型代表，其中恶性细胞仅占肿瘤的一小部分，依赖来自微环境的信号以维持生存。通过具有空间和单细胞分辨率的全基因组转录组分析，我们发现恶性细胞周围的邻域形成了一个由31种非恶性细胞类型组成的独特生态位，该生态位富含辅助性T细胞和髓系细胞，但缺乏浆细胞。此外，我们的空间分析提出IL13为潜在的生存因子。重组IL13在体外可促进恶性细胞生长，而针对超过1000种人类癌细胞系的全基因组失功能筛选显示，IL13受体的异源二聚体成分IL4R和IL13RA1在霍奇金淋巴瘤中具有独特的必需性。重要的是，阻断性抗体可模拟基因失活的效应。我们的研究结果为在霍奇金淋巴瘤中测试已获FDA批准的IL13靶向治疗提供了生物学依据。

### 第二部分 AI 大师评价

本研究旨在解析霍奇金淋巴瘤的微环境组成及其对肿瘤细胞生存的调控机制。作者利用全基因组尺度的空间转录组和单细胞分析技术，系统描绘了肿瘤周围非恶性细胞的构成特征，并确定IL13可能是关键的生存信号。功能性实验和基因失功能筛查均验证了IL13受体复合物在霍奇金淋巴瘤中的重要作用。研究创新性地将空间组学与功能基因组学结合，为IL13靶向治疗提供了实验证据，但仍需进一步临床验证以评估治疗效果与安全性。

---

## 15. 高盐饮食诱导黑色素瘤的免疫非依赖性再分化、代谢关闭及细胞周期停滞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422056)
**期刊：** Cell death & disease
**PMID：** 41422056
**DOI：** 10.1038/s41419-025-08329-x

### 第一部分 原文与翻译

**英文原标题：** High-salt diet induces immune-independent re-differentiation, metabolic shut down and cell cycle arrest of melanoma.

> **英文摘要：**
> High salt diet (HSD) is known to reduce cancer growth in some tumor models, which has been attributed to tissue accumulation of sodium that enhances local anti-tumor immunity. Here, we show that a HSD inhibits melanoma growth independent of sodium accumulation and immune cells in skin and lung. Melanoma cells from mice on a HSD upregulated the metabolic inhibitor Tuberous sclerosis complex 2 (TSC2), causing metabolic shutdown despite nutrient availability. Furthermore, Microphthalmia-associated transcription factor (MITF), a crucial regulator of melanoma metabolism and differentiation, was upregulated, resulting in enhanced melanogenesis and cell cycle arrest. Thus, a HSD reversed the de-differentiation of melanoma cells and promoted their re-differentiation into a "normal" melanocytic state. These findings suggest that the anti-tumor effect of HSD may be tumor-specific and in some cases immune cell-independent.

> **中文摘要：**
> 高盐饮食（HSD）在某些肿瘤模型中已知可抑制癌症生长，这一作用被归因于钠在组织中的积累，从而增强了局部的抗肿瘤免疫。本文指出，HSD 抑制黑色素瘤的生长与皮肤和肺中的钠积累及免疫细胞无关。来自摄入 HSD 的小鼠的黑色素瘤细胞上调了代谢抑制因子结节性硬化复合物 2（TSC2），尽管营养物质充足，却引起代谢关闭。此外，黑色素瘤代谢与分化的关键调控因子——小眼畸形相关转录因子（MITF）上调，导致黑色素生成增强及细胞周期停滞。因此，HSD 可逆转黑色素瘤细胞的去分化状态，并促进其重新分化为“正常”的黑素细胞样状态。这些发现提示，HSD 的抗肿瘤作用可能具有肿瘤特异性，并且在某些情况下不依赖于免疫细胞。

### 第二部分 AI 大师评价

该研究旨在探究高盐饮食对黑色素瘤生长的影响及其是否依赖免疫机制。作者通过小鼠模型发现，高盐饮食可通过上调 TSC2 抑制代谢并诱导细胞停滞，同时提高 MITF 表达促进再分化，而不依赖于免疫细胞或钠积累。这揭示了高盐饮食可能通过代谢重编程实现特异性抗肿瘤作用。研究创新性在于发现了免疫非依赖性的抗瘤机制，但其机制的普适性仍需其他肿瘤类型验证。

---

## 16. miRquad：首个基于数字PCR的TaqMan™多重高级临床研究检测，用于头颈癌中微RNA的检测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41422030)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41422030
**DOI：** 10.1186/s13046-025-03590-6

### 第一部分 原文与翻译

**英文原标题：** miRquad: first-in-class dPCR multiplex TaqMan™ Advanced clinical research assay for microRNA detection in head and neck cancer.

> **英文摘要：**
> BACKGROUND: Cancer resistance is one of the major challenges in oncology, often resulting in disease relapse and poor patient outcomes. Within the RNA family, microRNAs (miRNAs) regulate core biological processes and have been recognized also as critical contributors of tumor resistance and therapy failure. Being pivotal, they are increasingly exploited as biomarkers in various settings. Although in silico analyses facilitate miRNAs identification, PCR-based approaches remain essential to validate their expression. Currently, a plethora of well-established, single-target methods exist but multiplex detection from the same input have been only rarely explored.
> 
> METHODS: We present miRquad, the first-in-class digital PCR (dPCR) TaqMan™ multiplex clinical research assay for miRNA detection in head and neck (HNC) cancers. Based on a patented prognostic signature including miR-21-5p, miR-96-5p, miR-21-3p and miR-429, the assay would enable simultaneous miRNA analysis via qPCR and dPCR on multiple clinically relevant sample types.
> 
> RESULTS: We designed and optimized miRquad using both synthetic controls and retrospective patient-derived tissues, sera and saliva. A multicentre ring study was conducted to evaluate assay reliability across different platforms, demonstrating strong correlation with commercial singleplexes, broad applicability, reduced turnaround time (TAT) and cost-effectiveness. Finally, we provide evidence for its potential clinical application to predict disease outcome in HNC, testing miRquad on tumoral and peritumoral tissues, sera and saliva samples collected throughout patient follow up.
> 
> CONCLUSIONS: The assay overcomes common challenges associated with multiple miRNAs detection, particularly in liquid biopsy samples (e.g., multiple pipetting issues, increased consumption of sample for multiple assessment, extended TAT for complete profiling) and provides robust and accurate detection, demonstrating potential for real-time patient monitoring and prognostication in HNC.

> **中文摘要：**
> 背景：癌症耐药性是肿瘤学中的主要挑战之一，常导致疾病复发和患者预后不良。在RNA家族中，微小RNA（miRNA）调控核心生物学过程，并已被认为是肿瘤耐药和治疗失败的重要参与者。由于其关键作用，它们正越来越多地被用作各种环境下的生物标志物。尽管计算分析有助于miRNA的识别，但基于PCR的方法仍是验证其表达的关键。目前，已有大量成熟的单靶点检测方法，但利用相同输入进行多重检测的研究仍然罕见。
> 
> 方法：我们提出miRquad——首个基于数字PCR（dPCR）的TaqMan™多重临床研究检测，用于头颈癌（HNC）中的miRNA检测。该检测基于包含miR-21-5p、miR-96-5p、miR-21-3p和miR-429的专利预后特征，可实现对多种临床相关样本类型同时通过qPCR和dPCR进行miRNA分析。
> 
> 结果：我们利用合成对照和回顾性患者来源的组织、血清及唾液样本对miRquad进行了设计与优化。通过多中心环状研究评估了该检测在不同平台上的可靠性，结果显示与商业化单重检测具有高度一致性，且具有广泛适用性、缩短的检测周期（TAT）及良好的成本效益。最后，我们提供了其潜在临床应用的证据，即利用miRquad在头颈癌患者随访期间采集的肿瘤及肿瘤周围组织、血清和唾液样本上预测疾病结局。
> 
> 结论：该检测克服了多miRNA检测中的常见挑战，尤其是在液体活检样本中（例如多次移液、样本消耗过大、为完成全谱分析所需时间过长），并实现了稳健且精确的检测，展示出其在头颈癌中用于实时患者监测和预后评估的潜力。

### 第二部分 AI 大师评价

本研究开发了首个用于头颈癌微RNA检测的数字PCR多重TaqMan™检测miRquad，创新性地实现了多靶点miRNA的同步分析。研究通过多中心验证证明该方法在不同平台中具有可靠性、广泛适用性和高成本效益，并在组织、血清及唾液等多种样本中表现出优异的性能。其结果显示该检测可用于实时临床监测及预后评估，具有显著的转化潜力。创新点在于克服了液体活检中多miRNA同步检测的技术瓶颈，但仍需进一步在更大样本量中验证其临床预测价值。

---

## 17. 更正：《通过高效癌症靶向递送与优化序列间隔方案实现的免疫纳米囊泡串联增强化学免疫治疗》。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41420836)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41420836
**DOI：** 10.1002/advs.202520147

### 第一部分 原文与翻译

**英文原标题：** Correction to "Immunogenic Nanovesicle-Tandem-Augmented Chemoimmunotherapy via Efficient Cancer-Homing Delivery and Optimized Ordinal-Interval Regime".

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该文献是一篇针对原始研究论文的更正通知，其内容与纳米囊泡介导的化学免疫治疗策略有关。虽然本文并未提供新的实验数据或摘要信息，但表明作者或期刊对先前研究进行了修订或澄清。此类更正体现了科研透明度和学术严谨性的维护，提示读者应参考更新后的原文以获取准确信息。

---

速递结束，祝您工作愉快！